Abera Bioscience

Abera Bioscience Liabilities

The The Liabilities of Abera Bioscience (ABERA.SL) as of Oct 17, 2026 is 9.28 M SEK. In the previous year, The Liabilities was 4.95 M SEK — a change of 87.59% (higher).

Liabilities

9.28 MSEK

YoY

87.59%

Last updated:

In 2025, Abera Bioscience's total liabilities amounted to 9.28 M SEK, a 87.59% difference from the 4.95 M SEK total liabilities in the previous year.

The Abera Bioscience Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
2.02 M SEK
Jan 1, 2019
816,000.00 SEK
Jan 1, 2020
2.54 M SEK
Jan 1, 2021
2.22 M SEK
Jan 1, 2022
2.80 M SEK
Jan 1, 2023
3.69 M SEK
Jan 1, 2024
4.95 M SEK
Jan 1, 2025
9.28 M SEK
The Abera Bioscience Liabilities history
YEARLiabilitiesYoY
9.28 MSEK+87.59%
4.95 MSEK+33.96%
3.69 MSEK+32.13%
2.80 MSEK+25.85%
2.22 MSEK-12.49%
2.54 MSEK+211.03%
816,000.00SEK-59.68%
2.02 MSEK+118.57%
926,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Abera Bioscience's Liabilities

Abera Bioscience's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Abera Bioscience's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Abera Bioscience's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Abera Bioscience's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Abera Bioscience’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Abera Bioscience stock

The Liabilities of Abera Bioscience is 9.28 M SEK in 2025.

The Liabilities of Abera Bioscience changed from 4.95 M SEK to 9.28 M SEK, representing a 87.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Abera Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Abera Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Abera Bioscience